Promomed will pay dividends for 3 months of 2026 for 1.7 billion rubles. This is stated in the company's message.
8 rubles were accrued per share. The deadline for payment is July 24, 2026.
As reported in the company's financial statements, the group did not declare or pay dividends during 2025, 2024 and 2023. In 2025, the group made other capital distributions in favor of the owners in the amount of RUB 473.243 million, taking into account the restoration of the previously recognized estimated liability. In 2024, the group made other capital distributions in favor of the owners in the amount of RUB 13.753 million. In 2023, the group made other capital distributions in favor of the owners in the amount of RUB 292.133 million.
In March 2026, the company's board of directors decided to exclude from the dividend policy the requirement for a positive operating cash flow as a prerequisite for the payment of dividends. The change will allow the company to consider the economic validity of payments in the broader context of financial results while maintaining a balanced approach to capital allocation between investments in growth and creating shareholder value, the company said earlier.
PJSC Promomed (the parent company of the group) was established on July 16, 2021.
As of December 31, 2025, the ultimate controlling owner of the group was Peter Bely. As of December 31, 2024, he owns 87.67% of the authorized capital, and 82.5% as of December 31, 2025. As of December 31, 2024, a 5.65% stake belonged to Promomed Holdings LLC, with 6.68% held nominally. In 2025, Promomed Holdings LLC transferred its stake to UK ARTES LLC (the management company of ZPIF Smaragd).
As of December 31, 2025, the shareholders are: Peter Bely — 87.67%, other shareholders — 12.33%.
Non-controlling interests as of December 31, 2025: 10% in the authorized capital of Promark LLC, 50.44% (as of December 31, 2024, 49%) in the authorized capital of Berakhim LLC; 22.06% in the authorized capital of Promomed Holdings LLC; 31.98% (as of December 31, 2024, 30%) in the authorized capital of Promomed — Animal Health LLC"; 2.83% in the authorized capital of Miracle Farm LLC; 2.83% in the share capital of Biochemist JSC; 21.92% in the property of ZPIF Smaragd.
The net profit of PJSC Promomed under RAS for 2025 amounted to 123.45 million rubles against a loss of 69.375 million rubles a year earlier.
Promomed Group's net profit under IFRS for 2025 increased 2.5 times to 7.168 billion rubles from 2.87 billion rubles a year earlier. EBITDA increased by 86% to 15.3 billion rubles from 8.2 billion rubles, revenue increased by 75.2% to 37.57 billion rubles from 21.45 billion rubles.
Promomed Group's revenue for the first quarter of 2026 increased by 62.2% to RUB 7.3 billion. compared to a year earlier.
